<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848131</url>
  </required_header>
  <id_info>
    <org_study_id>15-005843</org_study_id>
    <nct_id>NCT02848131</nct_id>
  </id_info>
  <brief_title>Senescence in Chronic Kidney Disease</brief_title>
  <official_title>Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study goal is to assess the effect of senescent cell clearance on senescence burden,
      physical ability or frailty, and adipose tissue-derived mesenchymal stem cell (MSC)
      functionality in patients with chronic kidney disease (CKD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed studies will examine cellular senescence and the effect of senolytic therapy on
      senescent cell burden, frailty, and adipose-derived mesenchymal stem cell function in
      individuals with diabetic chronic kidney disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in proportion of senescent cells (representing the total senescent cell burden) present</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Assessment of senescence markers in skin, fat, and/or blood at baseline and day 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in proportion of senescent mesenchymal stem cells present</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Assessment of senescence markers in mesenchymal stem cells at baseline and day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mesenchymal stem cell function</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Assessment of functional studies in mesenchymal stem cells at baseline and day 14. Number of subjects with change in stem cell function related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Frailty index score</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Assessment by Fried and other frailty criteria at baseline and day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in kidney function</measure>
    <time_frame>Baseline, Day 14, Month 4, Month 12</time_frame>
    <description>Assessment by estimated and measured glomerular filtration rate at baseline, day 14, month 4, and month 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational Only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Dasatinib &amp; Quercetin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The drugs dasatinib and quercetin will be used in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: Dasatinib</intervention_name>
    <description>Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.</description>
    <arm_group_label>Group 2: Dasatinib &amp; Quercetin</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2: Quercetin</intervention_name>
    <description>Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.</description>
    <arm_group_label>Group 2: Dasatinib &amp; Quercetin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 40-80 years

          2. Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-45 ml/min/1.73m2

          3. Diabetes mellitus and taking diabetes medications

        Exclusion Criteria:

          1. Concomitant glomerulonephritis,

          2. Nephrotic syndrome,

          3. Solid organ transplantation,

          4. Autosomal dominant or recessive polycystic kidney disease,

          5. Known renovascular disease,

          6. Pregnancy,

          7. Active immunosuppression therapy,

          8. Hemoglobin A1câ‰¥11% at screening,

          9. History of active substance abuse (including alcohol) within the past 2 years,

         10. Current alcohol abuse (&gt;3 alcoholic beverages/day or &gt;21 per week),

         11. Body weight &gt;150 kg or body mass index&gt;50

         12. Human immunodeficiency virus infection

         13. Active hepatitis B or C infection

         14. Tyrosine kinase inhibitor therapy

         15. Known hypersensitivity or allergy to dasatinib or quercetin

         16. Inability to give informed consent

         17. Uncontrolled systemic lupus erythematosus

         18. Uncontrolled pleural/pericardial effusions or ascites

         19. New invasive cancer except non-melanoma skin cancers

         20. Invasive fungal or viral infection

         21. Inability to tolerate oral medications

         22. Total bilirubin&gt;2x upper limit of normal

         23. Subjects taking medications that are sensitive to substrates or substrates with a
             narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6 or strong inhibitors or
             inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus). If antifungals are
             absolutely necessary from an infectious disease perspective, then they will be allowed
             only if the levels are therapeutic.

         24. Subjects on strong inhibitors of CYP3A4.

         25. Subjects on therapeutic doses of anticoagulants (e.g. warfarin, heparin, low molecular
             weight heparin, factor Xa inhibitors, etc).

         26. Subjects on antiplatelet agents (e.g. full dose aspirin which is deemed mandatory for
             treatment, clopidogrel, etc.). Baby aspirin, if necessary for cardioprotection, will
             be allowed.

         27. Subjects on quinolone antibiotic therapy for treatment or for prevention of infections
             within 10 days

         28. Subjects taking H2-antagonists or proton pump inhibitors and unwilling to discontinue
             therapy 1 week prior and 2 weeks following enrollment.

         29. Corrected QT interval (QTc)&gt;450 msec
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LaTonya J Hickson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammie Volkman, RN</last_name>
    <phone>507-266-1944</phone>
    <email>volkman.tammie@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamara K Evans</last_name>
    <phone>507-266-1944</phone>
    <email>evans.tamara@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammie Volkman, RN</last_name>
      <phone>507-266-1944</phone>
      <email>volkman.tammie@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara K Evans</last_name>
      <phone>507-266-1944</phone>
      <email>evans.tamara@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>LaTonya Hickson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>LaTonya J. Hickson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

